Compare CCG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCG | TCRX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1M | 64.1M |
| IPO Year | N/A | 2021 |
| Metric | CCG | TCRX |
|---|---|---|
| Price | $0.98 | $1.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $350.00 | $8.50 |
| AVG Volume (30 Days) | 78.1K | ★ 823.7K |
| Earning Date | 11-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,290,042.00 | $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.91 |
| 52 Week High | $1.54 | $3.43 |
| Indicator | CCG | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 39.94 |
| Support Level | $0.93 | $0.99 |
| Resistance Level | $1.00 | $1.09 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 41.67 | 35.71 |
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.